Abstract
Diabetes mellitus and hyperglycemia are independent risk factors for morbidity, severe course, and adverse outcomes of a nevel coronavirus infection. The article discusses the features of the course of COVID-19 in patients with diabetes. Chronic hyperglycemia is associated with endothelial dysfunction, increased expression of pro-inflammatory cytokines, and a hypercoagulable state that aggravates the course of a viral infection. In turn, COVID-19 is associated with an increased risk of manifestation of diabetes mellitus, the SARS-CoV-2 virus can act as a potential trigger agent. There are still a number of unresolved questions, in particular, whether the virus can cause the manifestation of a special type of diabetes. No less relevant is the issue of optimal hypoglycemic therapy in patients with type 2 diabetes and COVID-19. Hypoglycemic therapy, by influencing various links in the pathogenesis of diabetes mellitus and lowering the level of glycemia, can potentially reduce the risks of complications and severe course of COVID-19 in patients with diabetes mellitus.
Key words: diabetes mellitus, COVID-19, hypoglycemic therapy.
For citation:El-Taravi Ya.A., Rassadina E.S., Kuzenkova N.S. et al. Impact of hypoglycemic drugs on the course of COVID-19 in patients with type 2 diabetes mellitus. Clinical review for general practice. 2023; 4 (4): 27–36. DOI: 10.47407/kr2023.4.4.00253
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.